Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers

Sung Jong Lee; Ji Geun Yoo; Jin Hwi Kim; Jeong Yeol Park; Jung Yun Lee; Yoo Young Lee; Dong Hoon Suh

doi:10.3802/jgo.2025.36.e72

Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers

Sung Jong Lee
, Ji Geun Yoo
, Jin Hwi Kim
, Jeong Yeol Park
, Jung Yun Lee
, Yoo Young Lee
, Dong Hoon Suh

Department of Obstetrics and Gynecology

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.

Original language	English
Article number	e72
Journal	Journal of Gynecologic Oncology
Volume	36
Issue number	1
DOIs	https://doi.org/10.3802/jgo.2025.36.e72
State	Published - Jan 2025

Bibliographical note

Publisher Copyright:
© 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.

Keywords

Gynecologic Neoplasms
Immunoconjugates
Immunotherapy
Molecular Targeted Therapy
Poly(ADP-Ribose) Polymerase Inhibitor

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3802/jgo.2025.36.e72

Cite this

@article{b1ae1d871ac14e1585659530bfd7679c,

title = "Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers",

abstract = "This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.",

keywords = "Gynecologic Neoplasms, Immunoconjugates, Immunotherapy, Molecular Targeted Therapy, Poly(ADP-Ribose) Polymerase Inhibitor",

author = "Lee, \{Sung Jong\} and Yoo, \{Ji Geun\} and Kim, \{Jin Hwi\} and Park, \{Jeong Yeol\} and Lee, \{Jung Yun\} and Lee, \{Yoo Young\} and Suh, \{Dong Hoon\}",

note = "Publisher Copyright: {\textcopyright} 2025. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.",

year = "2025",

month = jan,

doi = "10.3802/jgo.2025.36.e72",

language = "English",

volume = "36",

journal = "Journal of Gynecologic Oncology",

issn = "2005-0380",

publisher = "Korean Society of Gynecologic Oncology and Colposcopy",

number = "1",

}

TY - JOUR

T1 - Gynecologic oncology in 2024

T2 - breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers

AU - Lee, Sung Jong

AU - Yoo, Ji Geun

AU - Kim, Jin Hwi

AU - Park, Jeong Yeol

AU - Lee, Jung Yun

AU - Lee, Yoo Young

AU - Suh, Dong Hoon

PY - 2025/1

Y1 - 2025/1

N2 - This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.

AB - This review summarized the results of clinical trials in 2024 that were believed to have a significant impact on clinical practice in the field of gynecologic oncology. The SHAPE trial, INTERLACE and KEYNOTE-A18 trials, and BEATcc and COMPASSION-16 trials were included in early-stage, locally advanced, and recurrent/metastatic cervical cancer, respectively. For uterine corpus cancer, updated survival data of the four trials (NRG-GY018, RUBY, AtTEnd, DUO-E) for endometrial cancer and the first survival data of LMS-04 trial for leiomyosarcoma were described. For ovarian cancer, the final overall survival results of PRIMA study were followed by DUO-O, ATHENA-combo, and FIRST-ENGOT-OV44 trial in different disease conditions. Finally, the results of DESTINY-PanTumor02, a basket trial of trastuzumab deruxtecan, were briefly addressed.

KW - Gynecologic Neoplasms

KW - Immunoconjugates

KW - Immunotherapy

KW - Molecular Targeted Therapy

KW - Poly(ADP-Ribose) Polymerase Inhibitor

UR - https://www.scopus.com/pages/publications/85217070871

U2 - 10.3802/jgo.2025.36.e72

DO - 10.3802/jgo.2025.36.e72

M3 - Review article

C2 - 39900347

AN - SCOPUS:85217070871

SN - 2005-0380

VL - 36

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

IS - 1

M1 - e72

ER -

Gynecologic oncology in 2024: breakthrough trials and evolving treatment strategies for cervical, uterine corpus, and ovarian cancers

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this